Miltefosine and polyhexamethylene biguanide: a new drug combination for the treatment of <scp>A</scp>canthamoeba keratitis

Polat, Zübeyde Akın; Walochnik, Julia; Obwaller, Andreas; Vural, Ayşe; Dursun, Ayhan; Arıcı, Mustafa Kemal

doi:10.1111/ceo.12120

Cited by 52 publications

(23 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A combination of miltefosine and olyphexamethylene biguanide is effective for treatment of Acanthamoeba keratitis infection [45]. Langerhans cell histiocytosis (LCH) is a rare disorder predominantly occurring in infants and children.…”

Section: Existing Drug Combination Therapiesmentioning

confidence: 99%

“…Several types of DDI have been identified and characterized. An adverse DDI could be pharmacodynamic (PD) (target) in origin [45]; however the most common and best characterized adverse DDIs are PK (ADME) in origin. An example of a victim–perpetrator pair is the combination of selective estrogen receptor modulator tamoxifen and selective serotonin reuptake inhibitor (SSRI) paroxetine.…”

Section: Potential For Drug–drug Interaction With Drug Combination Thmentioning

confidence: 99%

See 1 more Smart Citation

Drug combination therapy increases successful drug repositioning

Sun

Sanderson

Zheng

2016

Drug Discovery Today

302

210

View full text Add to dashboard Cite

Repositioning of approved drugs has recently gained new momentum for rapid identification and development of new therapeutics for diseases that lack effective drug treatment. Reported repurposing screens have increased dramatically in number in the past five years. However, many newly identified compounds have low potency; this limits their immediate clinical applications because the known, tolerated plasma drug concentrations are lower than the required therapeutic drug concentrations. Drug combinations of two or more compounds with different mechanisms of action are an alternative approach to increase the success rate of drug repositioning.

show abstract

Section: Existing Drug Combination Therapiesmentioning

confidence: 99%

Section: Potential For Drug–drug Interaction With Drug Combination Thmentioning

confidence: 99%

Drug combination therapy increases successful drug repositioning

Sun

Sanderson

Zheng

2016

Drug Discovery Today

302

210

View full text Add to dashboard Cite

show abstract

“…This was carried out according to the procedure outlined by Polat et al [8]. In this assay, cell viability is assessed through the cleavage of tetrazolium salts, which are added to the culture medium, and for this, the water soluble tetrazolium (WST-1) labeling reagent (Roche, Mannheim, Germany) was used.…”

Section: Cell Proliferation Assaymentioning

confidence: 99%

Anti-biofilm and antimicrobial activity of Mentha pulegium L essential oil against multidrug-resistant Acinetobacter baumannii

Tutar¹,

Çelik²,

Karaman³

et al. 2016

Trop. J. Pharm Res

View full text Add to dashboard Cite

Purpose: To investigate the antimicrobial and anti-biofilm activities of essential oil from Mentha pulegieum L. (EOMP) on multi-drug resistant (MDR) isolates of A. baumannii, as well as its phytochemical composition, antioxidant properties and cytotoxic activity. Methods: The phytochemical composition of EOMP was analyzed by gas chromatography, while its antimicrobial activities were determined by disc diffusion and broth micro-dilution methods. Minimal biofilm inhibition concentration (MBIC) and minimal biofilm eradication concentration (MBEC) tests were used for assessment of its anti-biofilm properties. Viability in the biofilm was studied using 2,3-bis (2-methoxy-4-nitro-5-sulfophenyl)-2H-tetrazolium-5-carboxanilide (XTT) assay, while colorimetric assay was used to assess its cytotoxicity on L929 cellsResults: D-isomenthone, pulegone, isopulegone, menthol and piperitenone were the major components of the plant extract. EOMP produced > 22 mm inhibition zone for the isolates, with minimum inhibitory concentration respectively, while MBEC was ≥ 10 µL/msL. EOMP

show abstract

“…ПГМБГ и хлоргексидин, как сообщалось, были самой эффективной комбинацией препаратов, показавшей активность против цист и трофозоитов [5,12,[16][17][18]. Относительно этих двух препаратов важно упомянуть, что они активны против широкого спектра инфекционных агентов путем увеличения проницаемости цитоплазматической мембраны.…”

Section: медикаментозная терапия акunclassified

Treatment of Acanthamoeba keratitis

Marchenko

Kasparova

2016

Vestn. oftal'mol.

View full text Add to dashboard Cite

In recent years, Acanthamoeba keratitis (AK) has became a clinically significant problem because of the broad use of contact lenses that are the major risk factor of the disease. The treatment presents considerable difficulties due to similarity of clinical manifestations of AK to other keratites (bacterial, herpetic, and fungal). This often leads to late diagnosis and formation of drug-resistant cysts. There is currently no specific drug universally suitable for monotherapy of AK. Instead, 2 agents (usually chlorhexidine and poligexametilen biguanide) are used that, if combined, are effective against both trophozoites and cysts. If necessary (severe keratitis, insufficient treatment effect), diamidines (propamidine and its analogs), antifungals (fluconazole, itrakonazol), certain antibiotics (Neomycinum), and iodine-containing medications (povidone-iodine) can be prescribed. The use of corticosteroids is considered unjustified because of the risk of rapid progression (due to disturbance of local immunity and also provocation of excystation of the amoebas). The penetrative keratoplasty may be required, especially if a descemetocele or corneal perforation occurs, however, its results are generally worse than those in other keratites because of a higher risk of complications (iridocyclitis, secondary glaucoma, AK recurrence in the graft). In some cases, good results are achieved with minimally invasive surgeries, such as mechanical epithelial debridement, conjunctivoplasty and cryopreserved amniotic membrane transplantation, excimer laser phototherapeutic keratectomy, and cross-linking. In the future, gene therapy and specific chemotherapy of AK may well be developed.

show abstract

Miltefosine and polyhexamethylene biguanide: a new drug combination for the treatment of Acanthamoeba keratitis

Abstract: This in vivo study demonstrates that a miltefosine-polyhexamethylene biguanide combination is highly effective for the treatment of Acanthamoeba keratitis.

Cited by 52 publications

References 27 publications

Drug combination therapy increases successful drug repositioning

Drug combination therapy increases successful drug repositioning

Anti-biofilm and antimicrobial activity of <i>Mentha pulegium</i> L essential oil against multidrug-resistant <i>Acinetobacter baumannii</i>

Treatment of Acanthamoeba keratitis

Contact Info

Product

Resources

About